Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P242. Cost analysis of screening according to ECCO Guidelines for prevention of opportunistic infections in infliximab-treated IBD patients
P242. Factors associated with diagnostic delay in Crohn's disease (CD)
Authors:

S. Nahon1, P. Lahmek2, B. Lesgourgues1, C. Poupardin1, S. Chaussade3, L. Peyrin-Biroulet4, V. Abitbol3, 1Montfermeil, France, 2Limeil-Brevannes, France, 3Cochin, Paris, France, 4Vandoeuvre-les-Nancy, France

P242

Length of small bowel resection, SeHCAT retention value and frequency of diarrhoea: is there a link?

Authors:

A. Moore*, S. Langlands

Frimley Health NHS Foundation Trust, Gastroenterology, Frimley, United Kingdom

P243.

Development and initial validation of a unique score for in vivo differentiation of ulcerative colitis and Crohn's disease featuring confocal laser endomicroscopy

Authors:

G.E. Tontini1,2, J. Mudter3, M. Vieth4, R. Atreya1, C. Günther1, R. Kiesslich5, M. Vecchi2,6, M.F. Neurath1, H. Neumann1, 1University of Erlangen-Nuremberg, Medicine I, Erlangen, Germany, 2IRCCS Policlinico San Donato, Gastroenterology and Digestive Endoscopy Unit, San Donato Milanese, Italy, 3Sana Kliniken Ostholstein, Gastroenterology, Eutin, Germany, 4Klinikum Bayreuth, Institute of Pathology, Bayreuth, Germany, 5St. Marienkrankenhaus Katharina-Kasper, Medicine, Frankfurt am Main, Germany, 6University of Milan, Department of Biomedical Sciences for Health, Milan, Italy

P243. Faecal incontinence in inflammatory bowel disease: we don't ask and they don't tell
Authors:

J. Duncan1, G. Sebepos-Rogers1, O. Poole-Wilson2, J.B. Canavan3, C. To4, A. Stanton1, V. Kariyawasam1, M. Ward1, M. Sastrillo1, R. Goel1, K. Patel1, K. Taylor1, S. Anderson1, J. Sanderson1, P. Irving1, 1Guy's & St Thomas' Hospitals NHS Foundation Trust, IBD Centre, London, United Kingdom, 2South London Healthcare Trust, London, United Kingdom, 3King's College London, London, United Kingdom, 4Australian National University, Canberra, Australia

P243. Inflammatory bowel disease itself is a more important risk factor for impaired health-related quality of life than non-adherence to medical therapy
P243. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease
P243

Prevalence of extraintestinal manifestations in paediatric patients with Inflammatory Bowel Disease: Results from the Swiss IBD Cohort Study

Authors:

S. Vavricka*1, R. Rechner2, N. Fournier3, 4, G. Rogler1, P. Michetti5, V. Pittet3, E. Safroneeva6, A. Straumann7, C. Braegger8, A. Nydegger9, A. Schoepfer10

1University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2University Hospital Zurich, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 3Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 4University of Lausanne, IUMSP, Lausanne, Switzerland, 5Crohn and Colitis Center Clinique La Source , Gastroenterology, Lausanne, Switzerland, 6University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 7University of Basel, Gastroenterology and Hepatology, Basel, Switzerland, 8University of Zurich, Pediatric Gastroenterology, Zurich, Switzerland, 9University of Lausanne, Pediatric Gastroenterology, Lausanne, Switzerland, 10Centre Hospitalier Universitaire Vaudois, Gastroenterology and Hepatology, Lausanne, Switzerland

P244.

Development and initial validation of a new assessment tool for faecal incontinence in inflammatory bowel disease: the International Consultation on Incontinence Questionnaire: Inflammatory Bowel Disease (ICIQ-IBD)

Authors:

L. Dibley1, C. Norton1, N. Cotterill2, P. Bassett3, 1King's College London, Florence Nightingale School of Nursing & Midwifery, London, United Kingdom, 2British Urological Institute, Southmead Hospital, Bristol, United Kingdom, 3Statsconsultancy, Medical Statistician, Amersham, United Kingdom

P244. Factors associated with hyperhomocysteinemia in Portuguese patients with inflammatory bowel disease
Authors:

J. Magalhães1, B. Rosa1, M.J. Moreira1, M. Barbosa1, A. Rebelo1, S. Leite1, J. Cotter1, 1Alto Ave Hospital Center, Gastroenterology, Guimarães, Portugal

P244. Factors associated with the improvement of quality of life among Crohn's disease patients treated with adalimumab
P244. Prospective open-label pilot study to evaluate the safety, tolerability and efficacy of a novel adsorptive type cytapheresis module in patients with moderately to severely active ulcerative colitis
P244

Performance of Tuberculin skin test in routine screening for latent tuberculosis infection in patients with inflammatory bowel diseases

Authors:

C. Taxonera*1, 2, A. Ponferrada3, J.P. Gisbert4, F. Bermejo5, M.D. Martínez-Arranz6, M.L. de Castro7, P. López-Serrano8, M.I. Vera9, V. García-Sánchez10, A. Hernandez-Camba11, G. Bastida12, L. Fernandez-Salazar13, O. Merino14, R. Gómez15, D. Ceballos16, I. Morales17, C. Alba1, 2, D. Olivares1, 2, S. Riestra18

1Hospital Clínico San Carlos, IBD Unit, Madrid, Spain, 2Hospital Clínico San Carlos, IdISSC, Madrid, Spain, 3Hospital Infanta Leonor, Gastroenterology, Madrid, Spain, 4Hospital La Princesa , IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 5Hospital de Fuenlabrada, Gastroenterology, Madrid, Spain, 6University Hospital La Paz, Gastroenterology, Madrid, Spain, 7Complejo Hospitalario Universitario de Vigo, Gastroenterology, Vigo, Spain, 8Hospital Universitario Fundación Alcorcón, Gastroenterology, Madrid, Spain, 9Hospital Puerta de Hierro, Gastroenterology, Madrid, Spain, 10Hospital Reina Sofía, Gastroenterology, Córdoba, Spain, 11Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain, 12Hospital La Fe, Gastroenterology, Valencia, Spain, 13Hospital Clínico de Valladolid, Gastroenterology, Valladolid, Spain, 14Hospital de Cruces, Gastroenterology, Bilbao, Spain, 15Hospital Virgen de las Nieves, Gastroenterology, Granada, Spain, 16Hospital Dr. Negrín, Gastroenterology, Las Palmas de Gran Canaria, Spain, 17Hospital de Alcalá, Gastroenterology, Madrid, Spain, 18Hospital Central de Asturias, Gastroenterology, Oviedo, Spain

P245.

Determining patient & disease related risk factors for the development of clinical recurrence following ileocolic resection for Crohn's disease within a tertiary IBD unit

Authors:

P. Morar, J. Hodgkinson, S. Thalayasingam, K. Koysombat, O. Faiz, A. Hart, J. Warusavitarne, St Mark's Hospital, Colorectal Surgery & IBD Unit, London, United Kingdom

P245. Clinical and radiographic presentation of superior mesenteric vein thrombosis in Crohn's disease
P245. Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis
Authors:

J. Panés1, W.J. Sandborn2, H. Zhang3, D. Yu3, W. Niezychowski3, C. Su3, 1Hospital Clínic de Barcelona, CIBERehd, Department of Gastroenterology, Barcelona, Spain, 2University of California, Division of Gastroenterology, San Diego, La Jolla, CA, United States, 3Pfizer Inc, Collegeville, PA., United States

P245. The use of complementary therapies in inflammatory bowel disease – Do we know what our patients are taking?
P245

Accuracy of fecal M2-Pyruvate Kinase compared with fecal calprotectin to assess endoscopic severity in patients with inflammatory bowel diseases

Authors:

G. Boschetti*1, S. Boyer1, M. Chauvenet1, K. Stroeymeyt1, N. Benech1, J. Drai2, B. Flourié1, S. Nancey1

1Lyon-Sud Hospital, Gastroenterology, Pierre-Benite, France, 2Lyon-Sud Hospital, Biochemistry, Pierre Benite, France

P246.

Disease control and unmet needs among moderate to severe ulcerative colitis patients treated with conventional therapies in Europe: The UC CARES (Ulcerative Colitis condition, attitude, resources and educational study) study

Authors:

G. Van Assche1, L. Peyrin-Biroulet2, T. Fan3, M. Lynam4, S. Rojas-Farreras4, Q. Ding3, 1University Hospital Leuven, Gastroenterology, Leuven, Belgium, 2Nancy University Hospital, Université de Lorraine, Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France, 3Merck & Co., Inc, Global Health Outcomes, Whitehouse Station, United States, 4IMS Health, Health Economics and Outcomes Research, Barcelona, Spain

P246. Evaluation of a new point of care test for the screening of coeliac disease in an IgA deficient paediatric population
Authors:

F. Bienvenu1, L. Garnier1, F. Renosi1, J. Guillemaud1, S.I. Anghel2, A. Lachaux3, C. Besson Duvanel2, J. Bienvenu1, 1Lyon-Sud Hospital, Immunology Laboratories, Pierre-Bénite, France, 2Augurix SA, Monthey, Switzerland, 3Lyon Paediatric Hospital, Gastroenterology Hepatology Nutrition Department, Bron, France